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http:WHAT THIS PAPER ADDS
Despite the early promise of carotid artery stenting, we found that it accounts for less than 5% of carotid
revascularisation procedures in England. In contrast to the USA, the utilisation of carotid artery stenting (CAS) in
England did not increase between 2006 and 2012; cautious adoption may be appropriate given the inconclusive
evidence.Objective: We report the uptake, length of stay and vascular readmission rates of carotid endarterectomy (CEA)
and CAS among patients with symptomatic or asymptomatic carotid artery disease in the English National Health
Service (NHS).
Methods: Retrospective cohort study based on routinely collected Hospital Episode Statistics (HES) inpatient
data. We identiﬁed individual admissions for CEA (n ¼ 15996) or CAS (n ¼ 632) between 2006 and 2009.
Summary data were used to describe procedure volumes between 2009 and 2012. We analysed trends in
procedure use over time and used ordinary least squares regression to evaluate patient, clinical and
organisational characteristics associated with longer length of stay for revascularisation.
Results: CAS made up less than 5% of carotid revascularisation procedures; there was no trend for increasing use
between 2006 and 2012. Patients treated with CAS were on average younger, lived in areas of higher deprivation
and were more likely to have amaurosis fugax or a comorbidity of heart disease. CAS patients had a 19% (95% CI
14e24) shorter stay in hospital than CEA patients.
Conclusion: Despite the early promise of CAS and numerous randomised controlled trials evaluating efﬁcacy, it
has not been rapidly adopted in England. Cautious adoption may be appropriate given the higher periprocedural
risk of stroke or death after CAS, particularly in recently symptomatic patients.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In 2008, worldwide 7.3 million people died of ischaemic
heart disease and 6.2 million from stroke or other cere-
brovascular disease.1 Randomised controlled trials (RCTs)2,3
have proven the effectiveness of carotid endarterectomy
(CEA) versus best medical therapy alone in stroke preven-
tion among patients with symptomatic or asymptomatic
clinically signiﬁcant carotid artery stenosis. CEA is now one
of the most frequently performed elective surgical
procedures in the English National Health Service (NHS).
Carotid artery stenting (CAS) is a minimally invasive
procedure to treat carotid artery stenosis. CAS avoids any
risk of cranial nerve injury and has been shown to reduceresponding author. A.H.Y Lee, c/o Professor W Hollingworth, Can-
all, 39 Whatley Road, Bristol BS8 2PS, UK.
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//dx.doi.org/10.1016/j.ejvs.2013.04.019the incidence of perioperative myocardial infarction (MI).4
Early RCTs reported mixed evidence on the relative efﬁ-
cacy of CAS versus CEA in symptomatic patients and raised
concerns about safety.5 Recent larger trials have evaluated
CEA versus CAS with cerebral protection devices or ﬂow
reversal, both of which theoretically reduce periprocedural
strokes due to particulate debris.6e10 Meta-analyses of
these trials have shown that the risk of periprocedural
death or stroke is higher after CAS than CEA, but that long-
term incidence of death or disabling stroke is similar
between the two procedures.11 Pooled trial data suggest
that the difference in the periprocedural risk of stroke or
death between CAS and CEA is highest in symptomatic
patients treated within 7 days of symptoms.12
In September 2006, the UK National Institute for Health
and Clinical Excellence (NICE) guidance stated that CAS was
safe and efﬁcacious for symptomatic patients, but encour-
aged clinicians to audit outcomes and enter patients into
RCTs to resolve uncertainties about long-term efﬁcacy.13 In
April 2011 this guidance was updated,14 reafﬁrming the
A.H.Y. Lee et al. 283safety and efﬁcacy of CAS for symptomatic patients when
performed by a trained clinician in patients selected by a
multidisciplinary team. Concurrent NICE guidance for
asymptomatic patients15 concluded that the evidence on
efﬁcacy of CAS was inadequate, and that it should only be
used in the context of audit or research.
There is little evidence on how evolving evidence and
guidelines for CAS have inﬂuenced its uptake. The primary
aim of this study is to report trends in the use of CEA and
CAS among patients with symptomatic or asymptomatic
carotid artery disease in the English NHS between 2006 and
2012. The secondary aims are to compare length of stay and
inpatient mortality between patients treated with CEA and
CAS in routine practice and to describe readmission rates
for revascularisation and vascular events up to 4 years after
initial revascularisation.
MATERIALS AND METHODS
Measuring trends in procedure volumes
We used routinely collected Hospital Episode Statistics (HES)
data. HES contains details of all admissions (>14 million per
year) to NHS hospitals in England. It includes private patients
treated in NHS hospitals, patients who were resident outside
of England and care delivered by treatment centres (including
those in the independent sector) funded by the NHS.16
Procedures are recorded using the Ofﬁce of Population,
Censuses and Surveys (OPCS, 4th revision) codes and
diagnoses recorded using the International Classiﬁcation of
Diseases (ICD, 10th revision). HES provides information on
patient age, gender, ethnicity, index of multiple deprivation
(IMD17) score, hospital type (e.g. foundation hospitals
[typically larger hospitals with more ﬁnancial independence
from Government] or other NHS hospital), surgeon
specialty, and admission method (elective [e.g. from a
waiting list], emergency, other).
We identiﬁed patients who underwent either CEA (OPCS-
4 Codes L29.4, L29.5) or CAS (OPCS-4 Codes L31.4), as a
primary or secondary procedure between April 1, 2006, and
September 30, 2009. We selected patients with symptoms
of transient ischaemic attack (TIA), stroke or a diagnosis of
carotid artery stenosis (Appendix I). For each patient, the
index revascularisation was deﬁned as the ﬁrst CAS or CEA
procedure during our study period. Patients were excluded
if they received both CAS and CEA during an inpatient
episode (n ¼ 9), were less than 35 years old (n ¼ 4) or were
admitted for maternity care (n ¼ 1) leaving a cohort of
16,628 patients. We used ICD diagnosis codes to identify
patients who had symptoms of stroke, TIA, amaurosis fugax
or cardiovascular comorbidities (hypertension, heart dis-
ease, diabetes) at the time of revascularisation (Appendix I).
However, cerebrovascular disease is thought to be under-
recorded in HES, meaning that we cannot reliably distin-
guish between symptomatic and asymptomatic patients in
this dataset. In addition to these 2006e2009 patients, we
also used publicly available data16 on annual CAS and CEA
procedure volumes between 2010 and 2012 to examine the
most recent trends in procedure use.Identifying previous admissions and readmission rates
Each patient in the 2006e2009 cohort has a pseudony-
mised unique identiﬁer. We used this to identify previous
and subsequent hospital admissions. In the 6 months pre-
ceding the index revascularisation and in subsequent years
we identiﬁed admissions for cerebral infarction, TIA,
amaurosis fugax (Appendix I), CEA or CAS. In the years after
revascularisation we also identiﬁed admissions for
myocardial infarction (Appendix I). Data on inpatient
admissions were available up to March 31, 2010; hence at
least 6 months’ follow-up was available for all patients.
We investigated which patient, clinician and hospital-
related factors were associated with choice of procedure
using chi-square and Student t tests. We estimated the
bivariate association between procedure (CAS or CEA) and
episode length, inpatient mortality and readmissions using
chi-square, Student t tests and a non-parametric bootstrap
procedure. We used ordinary least squares multivariate
regression analysis to identify factors associated with length
of admission. We log-transformed the dependent variable,
episode length, due to the large positive skew and used
robust standard errors to account for variance in the error
terms. In our regression analysis we initially includedmultiple
patient (age, sex, ethnicity, IMD, private insurance), clinical
(cerebrovascular symptoms, cardiovascular comorbidities,
index revascularisation procedure, admission method), and
organisational (strategic health authority of residence,
foundation trust, number of stenting/endarterectomy pro-
cedures undertaken annually within the hospital) covariates.
We included the strategic health authority of residence to
allow for geographic differences in mean episode length and
readmission hazard.We removed variables if their effect size
was small and conﬁdence interval large, indicating no clini-
cally or statistically signiﬁcant association with length of stay.
The linearity of associations was evaluated by dividing the
distribution of continuous variables into deciles and esti-
mating the effect size in each decile. Analyses were per-
formed with STATA statistical software version 12.18RESULTS
Trends for intervention
In total there were 17,560 carotid procedures between April
1, 2006, and September 30, 2009, on 16,628 patients. CAS
made up less than 5% of all carotid revascularisation
procedures in each year of our study (Fig. 1). While the
number of CEA procedures per quarter increased steadily
from a minimum of 1,047 in quarter 2, 2006, to a maximum
of 1,378 in quarter 3, 2009; the trend for CAS was less clear.
The volume of CAS procedures peaked at 70 in quarter 3,
2008. The most recent publicly available data demonstrate
that the number of CAS procedures has not increased since
2009 (Fig. 1).
Patients treated with CAS were on average younger, lived
in areas of higher deprivation, were more likely to have had
a previous admission with a diagnosis of amaurosis fugax or
have heart disease recorded as a comorbidity. CAS patients
Table 1. Cohort characteristics.
Characteristic Endarterectom
N 15,996
Patient characteristics
Age (SD) 70.92 (9.10)
Male (%) 10,943 (68.41
White British (%) 12,973 (81.10
IMD (SD) 22.43 (15.90
Cerebrovascular admissions in previous 6 months (%)c
Stroke 2,682 (16.77
TIA 1,458 (9.11)
Amaurosis fugax 186 (1.16)
Procedures in previous 6 months (%)
Endarterectomy/stent 50 (0.31)
Admission details
Cerebrovascular symptoms or diagnoses recorded at presentation
Stroke 4,897 (30.61
TIA 939 (5.87)
Amaurosis fugax 667 (4.17)
Cardiovascular comorbidities
Hypertension 9,635 (60.23
Ischaemic heart disease 4,363 (27.28
Other forms of heart disease 1,879 (11.75
Diabetes 3,024 (18.90
Elective admission (%) 13, 113 (81.98
Consultant type (%)
General surgerye 14,653 (91.60
Neurosurgery 233 (1.46)
Radiology 3 (0.02)
Neurology 45 (0.28)
Other 1,062 (6.64)
Foundation Trust (%) 6,267 (39.18
IMD ¼ index of multiple deprivation; TIA ¼ transient ischaemic attack
a Student t test.
b Chi-square test.
c Deﬁnition: patients who had had one or more admissions with cer
previous 6 months.
d Deﬁnition: For symptoms at presentation (stroke, TIA or amaurosis fu
ipsi- or contralateral to the carotid artery revascularised.
e Includes the subspecialty of vascular surgery.
Figure 1. Carotid endarterectomy (CEA) and carotid artery stenting
(CAS) admissions per quarter. Solid line represents CAS procedures
per quarter. Dashed line represents CEA procedures per quarter.The
dotted lines at the right of the graph represent the estimated
quarterly rates of CAS and CEA based on annual procedure rates for
2010e2012 publicly reported by Hospital Episode Statistics online.
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revascularisation and to have the procedure performed in a
Foundation hospital while under the care of a radiologist or
neurologist (Table 1).Length of stay and inpatient mortality
While no difference was observed in mean episode length
(4.2 days CEA versus 4.3 days CAS, p ¼ .657; Table 2), a
higher proportion of patients treated with CAS had an
episode length of 2 days or less (60.5% CAS versus 40.5%
CEA). Inpatient mortality following either procedure was
infrequent (0.63% CAS versus 0.39% CEA; p ¼ .352).Follow-up and readmissions
Median follow-up time was 2.1 years, range 6 months to 4
years, and was similar for both CEA and CAS. A higher
proportion of CAS patients than CEA patients were read-
mitted to an NHS hospital during this period with a recor-
ded diagnosis of stroke (10.92% CAS versus 8.56% CEA,y Stent p Value
632
69.29 (9.52) <0.001a
) 415 (65.66) 0.145b
) 497 (78.64) 0.122b
) 25.88 (17.02) <0.001a
) 95 (15.03) 0.251b
63 (9.97) 0.465b
20 (3.16) <0.001b
1 (0.16) <0.001b
(%)d
) 209 (33.07) 0.189b
43 (6.80) 0.325b
32 (5.06) 0.272b
) 359 (56.80) 0.084b
) 229 (36.23) <0.001b
) 100 (15.82) 0.002b
) 129 (20.41) 0.343b
) 489 (77.37) 0.003b
) 257 (40.66) <0.001b
42 (6.65)
171 (27.06)
118 (18.67)
44 (6.96)
) 469 (74.21) <0.001b
.
ebrovascular symptoms or had had a carotid revascularisation in
gax) HES coding does not distinguish between symptoms that are
Table 2. Details of initial hospitalisation and subsequent readmission.
Characteristic Endarterectomy
N (%)a
Stent
N (%)a
p Value
N 15,996 632
Initial admission
Mean episode length (SD) 4.18 (6.73) 4.30 (8.30) 0.657b
Median episode length (IQR) 3 (2,4) 2 (1,4) <0.001c
0 days 246 (1.54) 97 (15.35)
1 days 2,245 (14.03) 67 (10.60)
2 days 3,980 (24.88) 218 (34.49)
3 days 4,034 (25.22) 86 (13.61)
4e5 days 2,886 (18.04) 49 (7.75)
6e7 days 1,069 (6.68) 38 (6.01)
8e13 days 907 (5.67) 38 (6.01)
14þ days 629 (3.93) 39 (6.17)
Inpatient mortality during initial hospitalisation 63 (0.39) 4 (0.63) 0.352d
Subsequent admissionse
Median follow-up years (IQR) 2.15 (1.31,3.04) 2.07 (1.34,2.95) 0.339c
Stroke 1,370 (8.56) 69 (10.92) 0.039d
TIA 475 (2.97) 24 (3.80) 0.231d
MI 562 (3.51) 32 (5.06) 0.039d
Endarterectomy/stent 975 (6.10) 28 (4.43) 0.085d
IQR ¼ interquartile range.
a Except where indicated otherwise.
b Student t test.
c Non-parametric bootstrap.
d Chi-square test.
e Because the diagnosis codes do not distinguish ipsilateral from contralateral symptoms, we do not know whether cerebrovascular
readmissions and subsequent revascularisations relate to the artery treated in the index admission.
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Fig. 2). No signiﬁcant differences were observed for hospital
readmission with a diagnosis of TIA (3.80% CAS versus
2.97% CEA, p ¼ .231) or in the number of second carotid
procedures (CEA 6.10% versus CAS 4.43%, p ¼ .085).
A multivariate analysis, adjusting for patient, clinical and
organisational characteristics, indicates that patients
treated with CAS had, on average, a 19% (95% CI 24e34%)
shorter hospital stay than those undergoing CEA (Table 3).
Length of stay was longer in patients who had an admission
diagnosis of stroke or TIA, had cardiovascular comorbidities,
were admitted as an emergency, were elderly, were female
or of non-white British ethnicity.DISCUSSION
Despite NICE guidance endorsing the short-term efﬁcacy of
CAS as an alternative to CEA in symptomatic patients with
high-grade carotid stenosis, we found no evidence that use of
CAS increased between 2006 and 2012. The actual numbers
of CAS remain small and have not grown despite an increase
in CEA numbers over the same time period. CAS was more
likely to be utilised in Foundation Hospitals and in younger
patients and those with a diagnosis of cardiac disease.
Our results are based on routinely collected hospital
episodedata that providea comprehensive overviewof trends
in the adoption of CAS. They also provide a description of
actual practice beyond the select patients, clinicians and
hospitals that participate in RCTs. Routine data facilitates
lengthy follow-up which is difﬁcult to achieve in RCTs.Therefore we are able to describe the medium-term read-
missions rates following carotid revascularisation in typical
practice.
The HES dataset undergoes data cleaning and quality
control, but coding errors occur.19 Previous work has
demonstrated that HES is a more complete census of
carotid revascularisation than voluntary registries.20 How-
ever inﬂexibility in HES coding means that techniques such
as CAS with embolus protection devices or the use of low
molecular weight heparin cannot be differentiated. Cere-
brovascular disease is thought to be substantially under-
recorded in HES.19 Our data conﬁrm this; approximately
40% of patients undergoing these carotid procedures had
cerebrovascular symptoms recorded in the HES dataset,
whereas registry data show that in excess of 80% of CEA
and CAS in the UK is performed in symptomatic
patients.21,22 We have described the readmission rates
following CEA and CAS in routine practice. However, more
accurate clinical data on symptoms would be needed to
perform a meaningful comparison of outcomes following
the two procedures.
Our results demonstrating low and static adoption of CAS
are in contrast to U.S. data describing an increase in CAS
utilization, particularly in asymptomatic patients, between
1998 and 2008, with a concurrent decline in CEA.23 In 2006,
CAS accounted for 20% of carotid revascularization pro-
cedures in the United States whereas our data suggest that
the proportion in England continued to be less than 5%.23
Our ﬁnding that CEA patients spent on average 1 day
longer in hospital is consistent with the ﬁndings of RCTs.24
Figure 2. Crude stroke/transient ischaemic attack (TIA) or myocardial infarction (MI) readmission rates by intervention. Readmission for
myocardial infarction (top) or stroke/TIA (bottom) after carotid endarterectomy (solid line) or carotid artery stenting (dashed line). The
ﬁgure presents crude readmission rates, not adjusted for symptom status or other factors that might affect readmission. HES data do not
allow us to differentiate readmissions for ipsilateral versus contralateral cerebrovascular events.
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lishing the role of CAS.Meaning of the study: implications for clinicians or
policymakers
Uncertainty on the appropriate use of CAS is inevitable
given the constantly evolving evidence. Early scepticism
about CAS in England is likely to have resulted from the
Leicester trial,24 which was stopped in 1998 due to a high
rate of post-CAS stroke. Our analysis period begins after the
publication of the SAPPHIRE trial of 334 symptomatic and
asymptomatic patients.6 The primary outcome, periopera-
tive death, stroke or MI or death or ipsilateral stroke within
1 year, was observed more frequently in the CEA group
(20.1%) than the CAS group (12.2%). The SAPPHIRE trial was
the ﬁrst to indicate that CAS might be superior in selected
‘high-risk’ patients.6 However, it was also accompanied by
commentaries questioning its methods and urging caution
in the use of CAS.25Table 3. Multivariate regression results identifying predictors of
initial hospitalisation length of stay.
Variable Episode length p Value
Ratio
Stent 0.81 (0.76, 0.86) <0.001
Cerebrovascular symptoms 1.06 (1.04, 1.08) <0.001
Cardiovascular comorbidities 1.12 (1.10, 1.14) <0.001
>80 Years old 1.11 (1.08, 1.14) <0.001
Female 1.06 (1.04, 1.08) <0.001
Emergency 1.43 (1.39, 1.48) <0.001
Non-white British 1.04 (1.01, 1.06) 0.003
Foundation Trust 0.97 (0.96, 0.99) 0.006In 2006 two European trials came to less positive con-
clusions about CAS. In the SPACE trial, which randomised
1,200 symptomatic patients, slightly higher rates of ipsilat-
eral ischemic stroke and death were observed after CAS;
CAS failed to meet criteria for non-inferiority versus CEA.7
The EVA-3S study also failed to show non-inferiority for
CAS in 527 symptomatic patients. Stroke and death rates
were higher with CAS and the trial was stopped early.8
The end of our analysis period covers the publication of
ICSS and CREST. ICSS enrolled 1713 symptomatic patients and
observed that the incidence of stroke, death or MI was
signiﬁcantly higher following CAS, 8.5%, than CEA, 5.2%.9 The
CREST trial randomized 2502 symptomatic and asymptomatic
patients.10 Periprocedural rates of death (0.7% CAS vs. 0.3%
CEA), stroke (4.1% CAS vs. 2.3% CEA) and MI (1.1% CAS vs.
2.3% CEA) differed between treatment groups. CAS patients
had better health-related quality of life outcomes in the ﬁrst
month after the procedure, but the difference diminished
and was not evident by 1 year.26 Stroke was associated with a
larger long-term impact on quality of life than MI; however,
MI is associated with poor long-term survival.4
We can speculate on the underlying reasons for the slower
diffusion of CAS in England than theUnited States. Regulation
and ﬁnancial incentives are likely factors. The Centers for
Medicare and Medicaid Services (CMS) in the US (March
2005) and NICE in England (September 2006) both endorsed
CAS in symptomatic patients, although NICE added the pro-
viso that patient outcomes should be monitored in research.
Hospitals in England were paid a ﬁxed tariff for “extracranial
arterial surgery” or “therapeutic endovascular procedures”
admissions. The lower tariff for the latter is a disincentive for
hospitals to incur the high instrumentation costs of CAS.
A.H.Y. Lee et al. 287Conversely the payments employed by Medicare and other
US insurers allow providers to charge more for CAS, although
reimbursement may still not cover cost.27 The ingrained
culture of competition between US hospitals and medical
specialties might also have encouraged interventionalists to
train in and adopt CAS.
Our ﬁnding that CAS procedures were more likely to be
performed in larger Foundation hospitals supports the
hypothesis that there is a lack of trained operators and facil-
ities in smaller English hospitals. However, given the volumee
outcome relationship observed for CAS,28 this centralization
in specialist centres may in fact be beneﬁcial for patients.
It is difﬁcult to judge whether the slow adoption of CAS in
England will be judged as appropriately cautious or unduly
laggardly. Recent meta-analysis estimated that CAS is
associated with higher long-term risks of stroke (pooled
odds ratio 1.37; 95% CI 1.13e1.65) and death or stroke
(pooled odds ratio 1.25; 95% CI 1.05e1.48), but lower risks
of periprocedural MI (pooled odds ratio 0.48; 95% CI 0.29e
0.78) and cranial nerve injuries.11 The authors concluded
that the outcomes of CEA seemed superior, but that in
younger patients the procedures may be equivalent.
In England, where the majority of procedures are per-
formed in symptomatic patients and the importance of
rapid intervention has been emphasised, concern that the
relative periprocedural risks of CAS are highest in patients
during the hyperacute period is also likely to be an impor-
tant factor in the slow adoption of CAS. The recently pub-
lished reanalysis of the EVA-3S, SPACE and ICSS data
supports this concern using pooled data stratiﬁed for delay
(0e7 days, 8e14 days and >14 days). Patients operated
upon within 7 days of their index symptoms undergoing
CAS had a risk of stroke or death of 9.4% (13/138)
compared with 2.8% (3/106) for patients undergoing CEA.12
There is limited cost-effectiveness data for CAS. The
SAPPHIRE investigators found that the higher procedural
cost of CAS (mean difference $4,081 per patient) was
largely offset by shorter hospitalization (mean difference
1.9 vs. 2.9 days).25 Economic evaluation of CREST conﬁrmed
the ﬁnding that the excess procedural costs of CAS were
largely offset by shorter hospitalization and that the cost of
the two procedures was broadly equivalent.29APPENDIX I. DEFINITION OF CONDITIONS.
Condition ICD-10 Cod
TIA, stroke or carotid artery stenosis Occlusion a
Cerebral inf
Stroke not
Transient ce
Other trans
Amaurosis
Cerebral at
Cerebrovas
Occlusion a
Atheroscler
Stricture of
AtherosclerUnanswered questions and future research
Recent relaxation of NICE guidance14,15 might increase uti-
lization of CAS in England, but the gap between England and
the US is likely to widen further if current discussion in the
US results in extended coverage of CAS.30 These debates
centre on identifying the subgroups of patients in which
CAS has equivalent or better value than CEA. The focus of
the debate may also be shifting; our data document a
general increase in carotid revascularizations, but this trend
may reverse if new trials ﬁnd that optimized medical ther-
apy is equivalent to revascularization in patients with low or
intermediate risk for stroke.
A broader question facing healthcare funders is how to
encourage genuine innovation while regulating medical in-
terventions that fail to live up to early promise. One option
that has received increasing attention is value-based reim-
bursement,31 whereby the amount the provider is paid for a
new procedure is directly linked to the degree to which it
has been proven to be cost-effective compared with exist-
ing best practice.
Despite the promise of CAS and more than 10 RCTs
published over a 12-year period, it has not been rapidly
adopted in the English NHS. In part this may be due to
reimbursements which do not encourage adoption of new
devices with high upfront costs. However, cautious adop-
tion may be appropriate given the inconclusive and evolving
evidence regarding postoperative myocardial infarction,
stroke and longer term cost-effectiveness. More deﬁnitive
evidence and clearer guidance on the patient subgroups in
which CAS is equivalent, or better than, CEA in terms of
safety, efﬁcacy and cost-effectiveness are needed to
establish its appropriate role in carotid revascularisation.
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None.es consistent with condition
nd stenosis of carotid artery (I652)
arction (I63)
speciﬁed as haemorrhage or infarction (I64)
rebral ischaemic attack, unspeciﬁed (G459)
ient cerebral ischaemic attacks and related syndromes (G458)
fugax (G453)
herosclerosis (I672)
cular disease, unspeciﬁed (I679)
nd stenosis of multiple and bilateral precerebral arteries (I653)
osis of other arteries (I708)
artery (I771)
otic heart disease (I251)
Continued
-continued
Condition ICD-10 Codes consistent with condition
Cerebral infarction Cerebral Infarction (I63)
Stroke not speciﬁed as haemorrhage or infarction (I64)
Hemiplegia (G819)
Sequelae of cerebral infarction (I693)
Sequelae of stroke, not speciﬁed as haemorrhage or infarction (I694)
Personal history of diseases of the circulatory systema (Z867)
TIA Transient cerebral ischaemic attack, unspeciﬁed (G459)
Other transient cerebral ischaemic attacks and related syndromes (G458)
Carotid artery syndrome (G451)
Amaurosis fugax Amaurosis fugax (G453)
Retinal vascular occlusions (H34)
MI Acute myocardial infarction (I21)
Subsequent myocardial infarction (I22)
Certain current complication following acute myocardial infarction (I23)
Hypertension Essential (primary) hypertension (I10)
Hypertensive heart disease (I11)
Hypertensive renal disease (I12)
Hypertensive heart and renal disease (I13)
Secondary hypertension (I15)
Ischaemic heart disease Unstable angina (I20.0)
Acute myocardial infarction (I21)
Subsequent myocardial infarction (I22)
Certain current complications following acute myocardial infarction (I23)
Other acute ischaemic heart diseases (I24)
Chronic ischaemic heart disease (I25)
Other heart disease Acute pericarditis (I30)
Pericarditis in diseases classiﬁed elsewhere (I32)
Acute and subacute endocarditis (I33)
Nonrheumatic mitral valve disorders (I34)
Nonrheumatic aortic valve disorders (I35)
Nonrheumatic tricuspid valve disorders (I36)
Pulmonary valve disorders (I37)
Endocarditis, valve unspeciﬁed (I38)
Endocarditis and heart valve disorders in diseases classiﬁed elsewhere (I39)
Acute myocarditis (I40)
Myocarditis in diseases classiﬁed elsewhere (I41)
Cardiomyopathy (I42)
Cardiomyopathy in diseases classiﬁed elsewhere (I43)
Atrioventricular and left bundle-branch block (I44)
Other conduction disorders (I45)
Cardiac arrest (I46)
Paroxysmal tachycardia (I47)
Atrial ﬁbrillation and ﬂutter (I48)
Other cardiac arrhythmias (I49)
Heart failure (I50)
Complications and ill-deﬁned descriptions of heart disease (I51)
Other heart disorders in diseases classiﬁed elsewhere (I52)
Diabetes Insulin-dependent diabetes mellitus (E10)
Non-insulin-dependent diabetes mellitus (E11)
Malnutrition-related diabetes mellitus (E12)
Other speciﬁed diabetes mellitus (E13)
Unspeciﬁed diabetes mellitus (E14)
a Includes personal history of TIA or cerebral infarction. This code was only used to identify symptomatic patients at the index admission
and not patients with a previous or recurrent cerebral infarction admission.
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